[HTML][HTML] Real-world effectiveness of mix-and-match vaccine regimens against SARS-CoV-2 Delta variant in Thailand: a nationwide test-negative matched case-control …
R Suphanchaimat, N Nittayasoot, C Jiraphongsa… - Vaccines, 2022 - mdpi.com
The objective of this study is to explore the real-world effectiveness of various vaccine
regimens to tackle the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS …
regimens to tackle the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS …
Further implications on the global real-world vaccine effectiveness against SARS-CoV-2
R Solante, C Alvarez-Moreno, E Burhan… - Expert Review of …, 2022 - Taylor & Francis
Dear Editor, We have recently reported a global review of vaccine effectiveness (VE) data
evaluating almost 80 real-world studies [1]. At the time of data extraction (10 February 2022) …
evaluating almost 80 real-world studies [1]. At the time of data extraction (10 February 2022) …
Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study
P Sritipsukho, T Khawcharoenporn… - Emerging microbes & …, 2022 - Taylor & Francis
Data on real-life vaccine effectiveness (VE), against the delta variant (B. 1.617. 2) of the
severe acute respiratory syndrome coronavirus 2 among various coronavirus disease 2019 …
severe acute respiratory syndrome coronavirus 2 among various coronavirus disease 2019 …
[HTML][HTML] Effectiveness of heterologous 3rd and 4th dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand.
S Chariyalertsak, K Intawong, K Chalom… - 2022 - europepmc.org
Abstract The Coronavirus disease 2019 (COVID-19) pandemic has evolved quickly, with
numerous waves of different variants of concern resulting in substantial morbidity and …
numerous waves of different variants of concern resulting in substantial morbidity and …
[HTML][HTML] Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in …
K Intawong, S Chariyalertsak, K Chalom… - The Lancet Regional …, 2023 - thelancet.com
Summary Background The Coronavirus disease 2019 (COVID-19) pandemic has evolved
quickly, with numerous waves of different variants of concern resulting in the need for …
quickly, with numerous waves of different variants of concern resulting in the need for …
[HTML][HTML] Effectiveness of inactivated COVID-19 vaccines against symptomatic, pneumonia, and severe disease caused by the delta variant: real world study and …
D Wu, Y Zhang, L Tang, F Wang, Y Ye, C Ma… - China CDC …, 2022 - ncbi.nlm.nih.gov
Knowledge of real-world performance of coronavirus disease 2019 (COVID-19) vaccines is
critically important for informing pandemic vaccination strategy and policy. As severe acute …
critically important for informing pandemic vaccination strategy and policy. As severe acute …
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and …
R Thiruvengadam, A Awasthi, G Medigeshi… - The Lancet Infectious …, 2022 - thelancet.com
Background SARS-CoV-2 variants of concern (VOCs) have threatened COVID-19 vaccine
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
effectiveness. We aimed to assess the effectiveness of the ChAdOx1 nCoV-19 vaccine …
[HTML][HTML] Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
Summary Background Protection against SARS-CoV-2 symptomatic infection and severe
COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination …
COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination …
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 …
S Niyomnaitham, Z Quan Toh… - Human Vaccines & …, 2022 - Taylor & Francis
We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary
schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and …
schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and …
[HTML][HTML] The pilot study of immunogenicity and adverse events of a COVID-19 vaccine regimen: priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) and …
S Mahasirimongkol, A Khunphon, O Kwangsukstid… - Vaccines, 2022 - mdpi.com
In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced
immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National …
immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National …